Consonance Capital Management LP Akebia Therapeutics, Inc. Transaction History

Consonance Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $16.8 Million - $92 Million	-7,031,283 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $600,300 - $1.22 Million	-90,000 Reduced 1.26%	7,031,283 $95.5 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $29.2 Million - $72.9 Million	7,121,283 New	7,121,283 $54 Million
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $5.87 Million - $11.5 Million	-1,430,579 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.41 - $8.73 $7.74 Million - $12.5 Million	1,430,579 New	1,430,579 $11.7 Million

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $338M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.